ArticleAdvances in therapy2026
Impact of Mucopolysaccharidosis Type II in Young Children from the Caregiver's Perspective: A Qualitative Study.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a rare, progressive X-linked lysosomal storage disorder that clinically manifests in children around 2-4 years of age. It affects nearly all organ systems, and in about two-thirds of patients, follows a severe neuronopathic course marked by developmental delay and cognitive decline. This study examined caregivers' perspectives on the most important symptoms and impacts of MPS II in young children.
methodsCaregivers of children aged 2-5 years with MPS II in the UK or USA were interviewed about the symptoms and impacts of MPS II in their child using a concept elicitation approach. A content analysis approach was used to analyze qualitative data collected.
resultsSixteen caregivers (n = 13 USA, n = 3 UK; mean age 34.0 years) of 16 children with MPS II participated. All 15 children for whom sociodemographic data were available were male and neuronopathic (mean age 4.2 years). All 16 caregivers reported cognitive decline in their child and disruption of family life. Other areas where MPS II burdens their children included problems with verbal communication/speech (n = 15), walking/climbing stairs (n = 15), hand movement (n = 15), hearing loss (n = 15), infection (n = 15), frustration (n = 14), interaction with non-family members (n = 14), nonverbal communication (n = 13), endurance (n = 13), stiff joints or muscles (n = 13), incontinence (n = 12), and skin issues (n = 10). Caregivers considered communication, mobility, and joint and muscle issues the "most bothersome" impacts.
conclusionDespite the availability of enzyme replacement therapy since 2006, MPS II substantially affects the lives of young children and their families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.